Ageing is associated with progressive endothelial dysfunction in normal humans. Flow-mediated dilation (FMD) of the brachial artery is impaired in elderly individuals with cardiovascular disease and vascular nitric oxide (NO) bioavailability is reduced. We investigated whether oral l-arginine, the substrate for NO synthesis, can improve impaired FMD in healthy very old people. In a prospective, double-blind, randomized crossover trial, 12 healthy old subjects (age 73.8 6 2.7 years) took l-arginine (8 g p.o. two times daily) or placebo for 14 days each, separated by a wash-out period of 14 days. FMD was determined by high-resolution ultrasound in the brachial artery during reactive hyperaemia. Baseline artery diameter was 3.88 6 0.18 mm. l-Arginine signi cantly improved FMD (to 5.7 6 1.2%, p , 0.0001), whereas placebo had no effect (-0.25 6 0.7%; n.s.). After l-arginine, plasma levels of l-arginine increased signicantly (114.9 6 11.6 versus 57.4 6 5.0 mmol/l), but placebo had no effect. As NO synthesis can be antagonized by its endogenous inhibitor asymmetric dimethyl l-arginine (ADMA), we determined ADMA plasma concentrations, which were elevated at baseline in comparison to healthy middle-aged individuals (3.9 6 0.2 versus 1.0 6 0.1 mmol/l; p , 0.0001). ADMA remained unchanged during treatment, but l-arginine supplementation normalized the l-arginine/ADMA ratio (p , 0.05). We conclude that in healthy very old age endothelial function is impaired and may be improved by oral l-arginine supplementation, probably due to normalization of the larginine/ADMA ratio.
Introduction
Nitric oxide (NO) is an endogenous anti-atherogenic molecule. Endothelial dysfunction, resulting from depressed NO bioavailability, has been demonstrated in the presence of atherosclerotic risk factors, 1 -4 even in the absence of angiographic evidence of atherosclerosis. 2 ,4 Moreover, the magnitude of coronary endothelial dysfunction was a potent predictor of major cardiovascular events. 5 Finally, interventions improving NO bioavailability, such as cholesterol lowering, 6 are able to favourably affect prognosis. Therefore, correction of endothelial dysfunction is of potential clinical relevance.
Ageing, a potent cardiovascular risk factor, is associated with progressive impairment of endothelial function. This has been proven for various indices of endothelial function, such as vasodilatory responses to acetylcholine or methacholine in the epicardial arteries, 4 ,7 coronary 4 ,7 and 8 resistance vessels, as well as the contribution of NO to acetylcholine-mediated forearm 9 and coronary dilation 4 and to basal vascular tone within the forearm 1 0 and coronary 4 a circulation. Flow-mediated dilation of the brachial artery is a useful noninvasive index of endothelial function, 1 which is decreased in the presence of atherosclerotic risk factors, 1 including age even in the subjects without known other risk factors, 1 1 as well as in the elderly without clinical evidence of cardiovascular disease.
Local intra-arterial administration of l-arginine, a substrate for NO synthesis, is known to improve impaired endothelial function within the coronary 1 2 and forearm 1 3 vascular beds in healthy old age, but without effect in younger subjects with normal endothelial function. To the best of our knowledge, in uence of oral l-arginine on endothelial function in the elderly has not been investigated. Therefore our aim was to investigate in a randomized, double-blind, placebo-controlled study if oral larginine can correct endothelial dysfunction in individuals older than 70 years. Furthermore, we determined in the present study whether plasma concentrations of asymmetric dimethylarginine (ADMA), characterized as an endogenous inhibitor of NO synthase, are elevated in healthy very old people compared with young and middle-aged subjects.
Methods

Subjects characterization
Healthy old subjects (n = 12) with no signs of cardiovascular disease (by a complete cardiovascular history and examination) were recruited by a newspaper article in the local press. Mean age was 73.8 years (range 70-78 years), eight were men and four women. Subjects were included only if they were asymptomatic, and lifelong nonsmokers.
Subjects with hypertension (de ned as chronically elevated blood pressure .150/90 mmHg), hypercholesterolaemia (total cholesterol .240 mg/dl), prior stroke, myocardial infarction, claudication, diabetes mellitus, liver disease and impaired renal function (creatinine clearance ,60 ml/min) were excluded from the study. No subjects were taking regular medications. The study protocol was approved by the Hannover Medical School Ethics Committee. Written informed consent was obtained from all subjects before the study.
Biochemical analyses
Blood samples were drawn into pre-chilled vacutainers containing EDTA, and immediately centrifuged. Plasma was stored at -20°C in appropriate aliquots until analyses.
Plasma concentrations of l-arginine, N G , N G -dimethylarginine (ADMA), and N G , N G -dimethylarginine (SDMA) were measured by high-performance liquid chromatography (HPLC) after precolumn derivatization with ophthaldialdehyde (OPA) by a modi cation of a previously published method. 1 4 Variability of the method was ,7%, and the detection limit of the assay was 0.15 mmol/l.
Plasma concentrations of insulin-like growth factor I (IGF-I) were determined by radioimmunoassay (RIA) (Nichols Institute, Bad Nauheim, Germany) with a detection limit of 0.06 ng/ml. Plasma concentrations of IGFbinding protein 3 (IGFBP-3) were also determined by RIA (Mediagnost, Tübingen, Germany) with a detection limit of 0.06 ng/ml. Plasma homocysteine concentrations were measured by a commercially available uorescence polarization assay (Abbott IMX, Abbott Diagnostics, Wiesbaden, Germany).
l-Arginine application and forearm blood ow measurement
In 12 healthy old subjects the effects of oral administration of l-arginine or placebo on endothelium-dependent, NOmediated vasodilation and on plasma l-arginine/ADMA ratio were studied in a double-blind, randomized, placebocontrolled crossover study. In randomized sequence the subjects received either 8 g of l-arginine twice daily or placebo for 14 days separated by a wash-out period of 14 days. Flow-induced vasodilation was assessed by a blinded operator as the increase in brachial artery diameter in response to reactive hyperaemia elicited by vascular occlusion. 1 , 1 5 It has been previously shown that owinduced vasodilation in the human brachial artery is largely due to the endothelial elaboration of NO. 1 6 ,1 7 All diameter measurements were made before l-arginine or placebo application for the particular day. Brachial artery diameter was measured at rest, during reactive hyperaemia, again at rest and after administration of sublingual glyceryl trinitrate (GTN) (0.4 mg), using a standard 10 MHz transducer (Sonolayer Toshiba). Measurements of brachial artery diameter were performed as previously described. 1 5 Increased ow was induced by in ation of a pneumatic tourniquet placed on the forearm into 200 mmHg, followed by rapid de ation after 5 min. The second scan was taken after 90 s, and the third scan after 120 s. Data in the graphs represent results after 120 s. After 15 min the procedure Vascular Medicine 2003; 8: 77-81 was repeated at rest and after GTN application for endothelium-independent dilator responses.
Venous blood samples were drawn at baseline and before l-arginine administration in the morning (fasting levels). Basal measurements of ow-dependent brachial artery vasodilation and plasma l-arginine/ADMA concentrations were also made in a group of young control subjects (12 men, mean age was 27.3 years (range 25-30 years); none of the subjects had a history of liver or renal disease or with diabetes mellitus, all subjects were nonsmokers. Total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides and creatinine clearance were in the normal range).
Statistical analyses
Data are presented as means 6 SEM. Differences between the effects of l-arginine versus placebo were tested using ANOVA, followed by the Fisher protected least signi cant differences. Linear regression curve and correlation coefcients were calculated according to the least squares method. Statistical signi cance was accepted for p , 0.05.
Results
Endothelial function
In the study group baseline diameter of the brachial artery was 3.88 6 0.18 mm. After two weeks, there was no signi cant difference in baseline arterial diameter either after l-arginine application (3.78 6 0.16 mm) or after placebo; placebo (3.92 6 0.19 mm) (p = NS). Flow-induced, NOmediated vasodilation of the brachial artery was 2.65 6 1.15% before l-arginine intake and 0.64 6 0.89% before placebo intake (p = NS) as compared with 11.00 6 3.4% in healthy young subjects (p , 0.01). Supplementation with oral l-arginine signi cantly enhanced endothelium-dependent vasodilation (to 5.73 6 1.19%, p , 0.05 versus baseline and p , 0.0001 versus placebo); whereas placebo had no signi cant effect (-0.25 6 0.7%, p = NS versus baseline) ( Figure 1 ).
Endothelium-independent vasodilation induced by nitroglycerine remained unchanged during the study period ( Figure 2 ).
Biochemical assays
The compliance was excellent and l-arginine has generally been well tolerated. One patient developed diarrhoea for one day in the l-arginine treatment phase, but completed the study. Plasma concentration of ADMA was signicantly elevated compared with the levels of healthy young subjects (3.86 6 0.2 mmol/l versus 1.06 6 0.04 mmol/l; p , 0.01). Neither l-arginine application nor placebo exerted a signi cant effect on ADMA concentrations in the very old subjects (4.00 6 0.34 mmol/l versus 4.23 6 0.47 mmol/l after l-arginine and placebo, respectively, p = NS). l-arginine levels were 58.9 6 3.4 mmol/l at baseline. They increased to 114.9 6 11.6 mmol/l after 14 days of l-arginine supplementation (p , 0.05) (fasting level in the morning) and were not signi cantly changed by placebo (53.2 6 3.9 mmol/l). l-arginine/ADMA ratio was signicantly increased by l-arginine supplementation, but unaffected by placebo ( Figure 3) .
Baseline ow-induced vasodilation was inversely corre- lated with plasma ADMA levels (R = 0.587, p , 0.01: Figure 4 ). Plasma concentrations of IGF-I were 91.9 6 7.3 mg/l before and 99.5 6 5.5 mg/l after l-arginine application (p = NS). Plasma concentrations of IGFBP-3 were 3.0 6 0.2 mg/l before and 2.7 6 0.2 mg/l after l-arginine intake (p = NS). Plasma concentrations of homocysteine were 12.4 6 0.7 mmol/l. 
Discussion
In our study subjects, FMD of the brachial artery was considerably impaired, being close to the values reported by the Cardiovascular Health Study Investigators (about 3.2%) 1 8 in the subjects older than 70 years in the absence of clinical evidence of cardiovascular disease. These values are also compatible with the extrapolation of data of Celermajer et al, 1 1 which revealed a gradual decline in FMD with increasing age in 238 asymptomatic subjects aged 15-72 years without known atherosclerotic risk factors.
In the present study, oral l-arginine improved diminished FMD despite an only two-to threefold increase in plasma l-arginine. This adds to the previously published studies reporting the ef ciency of l-arginine producing comparable increase in circulating l-arginine in conditions associated with a similar impairment of FMD. 1 4 ,1 7 In contrast to these reports, plasma l-arginine elevations of about 100-200% had no effects on FMD in the subjects whose basal FMD was higher. 1 9 ,2 1 Keeping in mind the known in uence of the cuff position on the magnitude of FMD during reactive hyperaemia, 2 2 only studies with the cuff on the forearm, i.e., comparable with our methodology, were taken into account in the above-mentioned considerations. Accordingly, it may be hypothesized that basal impairment of endothelial function is necessary for the bene cial effects of l-arginine on endothelial function to be revealed. It was reported that in patients with coronary atherosclerosis and/or its risk factors, the magnitude of the intracoronary l-arginine-induced improvement of epicardial and microvascular endothelium-dependent responses positively correlated with the degree of basal impairment of the endothelium-dependent vasomotion (l-arginine probably in millimolar range). 2 3 Moreover, in subjects with endothelial dysfunction of coronary resistance vessels and without signi cant coronary atherosclerosis on angiography, a sixmonth oral l-arginine therapy improved responses of epicardial and resistance vessels to acetylcholine despite increases in plasma l-arginine by less than 50%. 2 4 To our knowledge, there are no published studies focused on the comparison of responses of FMD to l-arginine in different age groups. However, the available data suggest that in this setting l-arginine appears to be effective exclusively in age groups with impaired endothelial function. Indeed, in subjects with normal coronary angiograms and without atherosclerotic risk factors, Chauhan et al demonstrated that intracoronary l-arginine considerably improved responses of blood ow to acetylcholine exclusively in healthy subjects 52-73 years old, in whom these responses were decreased compared with a subgroup below 50 years, where l-arginine produced no signi cant changes of coronary ow. 1 2 On the other hand, Taddei et al, 1 3 who were likely to have studied nal l-arginine concentrations comparable to those during oral therapy, 1 5 ,1 7 ,1 9 ,2 1 have shown in normotensives aged 60-73 years without coexistent diseases, that intrabrachial l-arginine partially normalized the attenuated acetylcholine-induced rises in forearm blood ow, but was ineffective in those younger than 30 years with intact endothelial function. However, in both the above-cited studies (by Taddei et al and Chauhan et al) only few subjects were older than 70 years, l-arginine levels were not measured, and acetylcholine, a common but nonphysiologicalstimulus for endothelial function testing, was used. It has to be admitted we are not able to completely exclude neurohumoral changes in our patients after l-arginine application in addition to the selective stimulation of the l-arginine/NO pathway, 2 5 but we measured IGF-I and IGFBP-3 as very reliable surrogate parameters for release of growth hormone and there was no effect. So we could exclude the stimulation of NO by the release of growth hormone. Nevertheless, in the present study the observed rises of plasma larginine seem too low to affect basal haemodynamics or to evoke hormonal changes. 2 5 The described association between impaired endothelial function and the ability of l-arginine to exert bene cial effects might be related to the accumulation of asymmetric ADMA, an endogenous inhibitor of NO synthesis, which was observed in our elderly subjects, as well as in the presence of atherosclerosis or its risk factors. 2 9 According to this concept, the competition between l-arginine and elevated ADMA for the same binding site within endothelial NO synthase could form a basis for both endothelial dysfunction and for the ability of exogenous l-arginine to produce biological effects despite the low k m of the enzyme for l-arginine 2 9 compared with intra-and extracellular concentrations of the amino acid, a so-called l-arginine paradox. In line with this hypothesis, assuming the relevance of ADMA accumulation for the de ciency of the activity of antiatherogenic NO, ADMA was not only an independent predictor of carotid 2 8 atherosclerosis, but was also recently identi ed as an independent cardiovascular risk factor in prospective clinical trials 2 9 ,3 0 . Also in agreement with the presented concept, plasma ADMA levels correlated better with endothelial vasodilator dysfunction than plasma LDLcholesterol levels did in untreated patients with hypercholesterolaemia. 1 4 It is noteworthy that in our elderly subjects we observed a signi cant independent relationship between ADMA and endothelial function. Moreover, as previously described for other conditions associated with ADMA (hypercholesterolaemia 1 4 ,1 5 and coronary 1 7 ,3 0 ), in our study group FMD was decreased and improved after l-arginine.
Recently, Stühlinger et al have reported that homocysteine post-translationally inhibits the activity of dimethylarginine dimethylaminohydrolase (DDAH), the enzyme that degrades ADMA, causing ADMA to accumulate at in vitro concentrations of homocysteine beginning from 30 mmol/l. 3 1 We determined homocysteine levels in our very old subjects that were in the normal range (between 5 and 15 mmol/l) and even low compared with homocysteine levels in older subjects which are regarded to be normal between 5 and 20 mmol/l. 3 2 This concentration makes clear that the very old people were really healthy, as the increased plasma homocysteine levels in old people are often explained by vitamin de ciency. It cannot be excluded that in vivo homocysteine concentrations as low as 12 mmol/l can be suf cient to reduce activity of DDAH, increasing ADMA accumulation. However, it seems unlikely that such a range of circulating homocysteine would be responsible for ADMA elevations of almost 300%, as observed in our very old subjects. Accordingly, in the elderly high ADMA concentrations do not appear to be secondary to a speci c abnormality but rather seem attributable to the effect of ageing by itself, by analogy to experimental data in aged rats. 3 3 Such rationale is in agreement with results of Miyazaki et al, 2 8 who identi ed age as the strongest independent positive predictor of plasma ADMA in 116 untreated subjects without clinical evidence of coronary or peripheral atherosclerosis.
In conclusion, in a randomized, double-blind, placebocontrolled crossover trial, we have demonstrated the ability of oral l-arginine to partially correct severely depressed endothelial function in healthy individuals older than 70 years. This suggests a novel therapeutic strategy all the more because neither pravastatin nor vitamin E were effective in correcting endothelial function in asymptomatic men older than 70 years with moderate hypercholesterolaemia. 3 4 Prospective placebo-controlled long-term observations with controlled oral l-arginine administration at doses similar to those in the present report are needed to clarify whether the favourable effect of l-arginine on endothelial function in healthy very old age can be extended into cardiovascular risk reduction in this population.
